#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14908	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2603	703.2	0	.	n	.	0	A69G	SNP	69	69	A	698	698	G	884	G,A	666,217	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14908	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2603	703.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	2079	2079	T	1024	T,C,A,G	1020,1,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14908	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2603	703.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1813	1813	C	941	C,G	940,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25792	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4134	779.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1972	1972	A	1034	A	1034	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25792	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4134	779.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2606	2606	C	944	C,T	943,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25792	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4134	779.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2680	2680	A	847	A,C	846,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25792	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4134	779.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3232	3232	C	932	C,T,A	930,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2428	folP	852	852	99.88	folP.l6.c4.ctg.1	1943	155.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1010	1012	AAA	247;245;242	A;A;A,G	247;245;241,1	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2428	folP	852	852	99.88	folP.l6.c4.ctg.1	1943	155.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1241	1243	AGC	251;247;249	A;G,A;C,T	251;246,1;248,1	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5210	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3854	168.7	1	SNP	p	S91F	0	.	.	271	273	TCC	767	769	TCC	190;192;191	T;C;C,T	190;192;190,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5210	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3854	168.7	1	SNP	p	D95N	0	.	.	283	285	GAC	779	781	GAC	196;197;198	G;A;C	196;197;198	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5210	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3854	168.7	1	SNP	p	D95G	0	.	.	283	285	GAC	779	781	GAC	196;197;198	G;A;C	196;197;198	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1944	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1872	129.5	1	SNP	p	G45D	0	.	.	133	135	GGC	834	836	GGC	229;228;227	G;G;C	229;228;227	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1170	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1466	99.3	0	.	n	.	0	A197.	DEL	197	197	A	876	876	A	242	A	242	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4770	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3432	173.2	1	SNP	p	D86N	0	.	.	256	258	GAC	824	826	GAC	227;226;227	G;A,C;C	227;225,1;227	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4770	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3432	173.2	1	SNP	p	S87I	0	.	.	259	261	AGT	827	829	AGT	226;225;225	A;G;T	226;225;225	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4770	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3432	173.2	1	SNP	p	S87W	0	.	.	259	261	AGT	827	829	AGT	226;225;225	A;G;T	226;225;225	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4770	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3432	173.2	1	SNP	p	S87R	0	.	.	259	261	AGT	827	829	AGT	226;225;225	A;G;T	226;225;225	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4770	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3432	173.2	1	SNP	p	S88P	0	.	.	262	264	TCC	830	832	TCC	225;226;227	T;C;C	225;226;227	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4184	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3173	164.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1825	1827	GGC	213;212;214	G;G;C	213;212;214	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1489	1491	GCA	251;252;252	G;C;A	251;252;252	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1492	1494	ATC	253;252;252	A,T;T,G,C;C	252,1;250,1,1;252	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1504	1506	GTG	248;249;250	G;T;G	248;249;250	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1504	1506	GTG	248;249;250	G;T;G	248;249;250	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2008	2010	ACC	221;222;223	A;C;C	221;222;223	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2062	2064	GCG	214;216;217	G;C,T,G;G	214;214,1,1;217	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2062	2064	GCG	214;216;217	G;C,T,G;G	214;214,1,1;217	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2185	2187	GGC	243;242;242	G;G;C,T	243;242;241,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2194	2196	GGC	251;254;255	G,C,A;G,T;C	248,2,1;253,1;255	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4198	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2846	184.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2212	2214	CTG	264;263;258	C;T,A;G,T	264;262,1;257,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5794	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3618	200.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1851	1853	CCG	226;227;223	C,T;C,G;G,A	225,1;226,1;222,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2456	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2353	130.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	850	850	C	185	C	185	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	A251V	NONSYN	751	753	GCG	10	12	GTG	29;30;32	G;T;G	29;30;32	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	S271T	NONSYN	811	813	TCG	70	72	ACT	105;105;105	A;C;T	105;105;105	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	76	78	GAT	105;105;105	G,C;A;T	104,1;105;105	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	79	81	AGT	105;105;105	A;G;T	105;105;105	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	N277H	NONSYN	829	831	AAC	88	90	CAC	105;105;105	C;A;C	105;105;105	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	R307K	NONSYN	919	921	AGA	178	180	AAA	2;2;3	A;A;A	2;2;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	T311A	NONSYN	931	933	ACA	190	192	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	E312D	NONSYN	934	936	GAA	193	195	GAC	4;4;4	G;A;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	F314I	NONSYN	940	942	TTC	199	201	ATC	4;4;4	A;T;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	A316S	NONSYN	946	948	GCG	205	207	TCG	4;4;5	T;C;G	4;4;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	V318A	NONSYN	952	954	GTC	211	213	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	G319S	NONSYN	955	957	GGC	214	216	AGC	5;5;5	A;G;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	G320A	NONSYN	958	960	GGT	217	219	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	386	porB1a	984	243	91.36	porB1a.l15.c30.ctg.2	331	48.4	0	.	p	.	0	G322V	NONSYN	964	966	GGT	223	225	GTT	5;5;5	G;T;T	5;5;5	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	T87A	NONSYN	259	261	ACT	765	767	GCT	209;209;210	G;C;T	209;209;210	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	771	773	AGC	208;206;205	A;G;C	208;206;205	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	K120D	NONSYN	358	360	AAG	864	866	GAC	234;234;234	G;A,C;C	234;233,1;234	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	E137K	NONSYN	409	411	GAA	915	917	AAA	260;254;254	A;A;A,C	260;254;253,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	933	935	CAA	250;254;255	C;A;A,G,C	250;254;253,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	957	959	GCA	259;261;264	G;C;A,G	259;261;263,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	T213A	NONSYN	637	639	ACA	1143	1145	GCA	270;272;276	G;C,G;A	270;271,1;276	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1263	1265	CAA	210;210;211	C;A;A	210;210;211	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	.	INDELS	760	761	AC	1267	1270	ATCA	208;208;204;198	A;T;C;A	208;208;204;198	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	.	INDELS	763	764	TG	1274	1276	AGT	190;191;194	A;G;T	190;191;194	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1281	1283	GAT	196;196;194	G;A;T	196;196;194	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1389	1391	AGT	225;223;223	A,G;G;T	224,1;223;223	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1395	1397	GAC	225;225;227	G;A;C,G	225;225;226,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2764	porB1b	1041	1041	97.42	porB1b.l6.c30.ctg.1	2112	162.9	0	.	p	.	0	E326K	NONSYN	976	978	GAA	1488	1490	AAA	238;238;241	A;A,G;A	238;237,1;241	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10258	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	5486	233.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2302	2304	CAT	258;257;259	C,A;A;T	257,1;257;259	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1480	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1551	119.0	1	SNP	p	V57M	1	.	.	169	171	ATG	775	777	ATG	262;261;258	A;T;G	262;261;258	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
